RxDoctor Payments DataLook up a doctor →

Kenneth Sunnergren, MD

Cardiovascular Disease · Lewes, DENPI 1720055122

Payments from drug & device makers

$10,727in general payments, 2019–2025

Across 450 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novartis$1K
  • Amgen$1K
  • Pfizer$806
  • AstraZeneca$801
  • E.r. Squibb & Sons, L.L.C.$786
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$5986%
  • Food & beverage$10,03794%
  • Education$931%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,727 in reported general payments places this provider in the 70th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$523,264
Medicare patients
2,277
Services billed
7,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban954$1,377,799
XareltoRivaroxaban227$313,055
EntrestoSacubitril/Valsartan181$307,120
JardianceEmpagliflozin154$228,923
Repatha SureclickEvolocumab81$111,448
OzempicSemaglutide37$55,936
TrulicityDulaglutide29$50,436
FarxigaDapagliflozin Propanediol46$46,206
WegovySemaglutide24$30,580
MultaqDronedarone Hcl17$30,018
Ezetimibe438$16,866
Metoprolol Succinate941$16,346
Praluent PenAlirocumab17$16,207
BrilintaTicagrelor13$15,978
Carvedilol ErCarvedilol Phosphate24$11,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$806$1,377,799954 claims
Johnson & JohnsonXarelto$534$313,055227 claims
NovartisEntresto$1,269$307,120181 claims
Boehringer IngelheimJardiance$322$228,923154 claims
Novo NordiskOzempic, Wegovy$455$86,51561 claims
AstraZenecaFarxiga, Brilinta$801$62,18459 claims
Lilly USA, LLCTrulicity$55$50,43629 claims
Sanofi-aventis U.S. LLCMultaq$228$30,01817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →